Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo‐controlled, double‐blind clinical trial
British Journal of Dermatology2018Vol. 180(2), pp. 297–305
Citations Over Time
Eggert Stockfleth, Günther F.L. Hofbauer, Uwe Reinhold, Georg Popp, Ulrich R. Hengge, Rolf‐Markus Szeimies, H. Brüning, M.D. Anliker, T. Hunger, Reinhard Dummer, Claas Ulrich, R. Kenzelmann, Christian Surber, Lars E. French
Abstract
Resiquimod 0·03% gel is more effective than 0·01% gel. From the perspectives of safety and tolerability, the lower concentration and shorter duration are preferable. The clinical response in arms 2/3 was reached with fewer gel applications. The dosing regimens that used the biological end point (arms 4/5) proved equally efficacious as predefined treatment durations and may therefore be suitable for personalized AK treatment.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Safety and Tolerability of Gabapentin as Adjunctive Therapy in a Large, Multicenter Study(1999)81 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Tolerability of topical antimicrobials in treatment of acne vulgaris.(2014)
- → TOPICAL MEDICINES IN THE TREATMENT OF ALLERGODERMATHOSIS(2017)